Patient P-01855
Therapy response
Declining
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
19%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S04
- Day 16 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 32 DT-01 recommended — Dosing / Timing Recommendation DT-01
- Day 33 Patient accepted — Started DT-01 in the companion
- Day 38 GI symptom burden −15% vs expected — Dosing / Timing Recommendation DT-01
- Day 44 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 16.
Primary contributors, last 14 days
- GI instability+5
- Inflammatory activity-4
- Treatment adherence-3
- Toxicity+3
What helped?
- Dosing / Timing Recommendation DT-01Day 32Result: symptom burden −15%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion21/100
worsening · +14.0 vs previous 14 d
Toxicity
Blood13.9/100
worsening · +2.3 vs previous 14 d
Sleep quality
Wearable44.8/100
worsening · -12.6 vs previous 14 d
Energy level
Daily log5.6/10
worsening · -0.7 vs previous 14 d
Stress level
Daily log4.3/10
worsening · +0.8 vs previous 14 d
Steps
Wearable8,603
worsening · -1,165 vs previous 14 d
Adherence
Companion94.6 %
stable · -1.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 80 from the failing basin, 7 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load-1.6no signal · 27%
- Histamine load-1.1no signal · 29%
- Alcohol-1no signal · 23%
- Simple carbohydrates+0.8no signal · 17%
- Spicy / capsaicin-0.5no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.1 · butyrate capacity 66/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 57 ms
- Sleep
- 6.8 h
- Steps
- 7,538
- Resting HR
- 68 bpm
Daily log: GI score 21, nutritional resilience 69, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 35% | S05 | AD-05 | no change | 90 |
| P-01804 | 30% | S19 | AD-05 | improved | 61 |
| P-01541 | 29% | S09 | AD-05 | no change | 43 |
| P-01677 | 42% | S05 | BR-03 | no change | 86 |
| P-01329 | 38% | S08 | BR-03 | improved | 79 |
| P-01495 | 35% | S07 | BR-03 | improved | 85 |
| P-01689 | 29% | S13 | BR-03 | no change | 50 |
| P-01654 | 33% | S08 | CR-01 | improved | 85 |
| P-01430 | 28% | S05 | CR-01 | improved | 54 |
| P-01479 | 44% | S15 | DT-01 | improved | 84 |
| P-01724 | 36% | S10 | DT-01 | improved | 63 |
| P-01522 | 34% | S06 | DT-01 | no change | 62 |